Molecular and Cellular Biochemistry

, Volume 374, Issue 1–2, pp 233–238

Paraoxonase 1 L55M, Q192R and paraoxonase 2 S311C alleles in atherothrombosis

  • L. Cozzi
  • J. Campolo
  • M. Parolini
  • R. De Maria
  • M. C. Patrosso
  • A. Marocchi
  • O. Parodi
  • S. Penco
Article

Abstract

Increased oxidative stress is known to play a role in the pathogenesis of atherosclerosis, and polymorphisms in genes encoding for enzymes involved in modulation of oxidant stress, such as paraoxonases (PONs), provide a potentially powerful approach to study the risk of disease susceptibility. Aim of our study is to investigate the possible association among PONs polymorphisms, clinical and metabolic factors, and atherothrombotic events in an Italian population. We evaluated in 105 subjects, with or without atherosclerotic risk factors, the presence of PON1 L55M, PON1 Q192R, and PON2 S311C genetic variants, as well as lipid profile, the concentration of aminothiols (blood reduced glutathione, plasma total glutathione, homocysteine, cysteine, cysteinyl glycine), and malondialdehyde as markers of lipid peroxidation. Clinical, biochemical, and genetic variables were correlated with a history of atherothrombosis. Previous atherothrombotic events were found in 42 patients (40 %): myocardial infarction in 24, stroke or transient ischemic attack in 18. By multiple logistic regression analysis, hypertension (OR = 5.538; 95 % CI 2.202–13.902, P < 0.001), HDL-cholesterol concentration (OR = 0.947; 95 % CI 0.910–0.985, P = 0.007), and the presence of C allele in PON2 gene (OR = 3.595; 95 % CI 1.247–10.361, P = 0.018) were independently associated with atherothrombotic events. Our study sheds light on the role of PON2 as a possible cofactor in determining the risk of events together with the well-known risk markers HDL-cholesterol and hypertension.

Keywords

Paraoxonase Oxidative stress Aminothiols Atherothrombosis 

References

  1. 1.
    Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256:2835–2838PubMedCrossRefGoogle Scholar
  2. 2.
    Kerkeni M, Addad F, Chauffert M, Chuniaud L, Miled A, Trivin F, Maaroufi K (2006) Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease. Clin Biochem 39:821–825. doi:10.1016/j.clinbiochem.2006.05.010 PubMedCrossRefGoogle Scholar
  3. 3.
    Jakubowski H (2000) Calcium-dependent human serum homocysteine thiolactone hydrolase A protective mechanism against protein N-homocysteinylation. J Biol Chem 275:3957–3962. doi:10.1074/jbc.275.6.3957 PubMedCrossRefGoogle Scholar
  4. 4.
    Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST (2001) Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 276:44444–44449. doi:10.1074/jbc.M105660200 PubMedCrossRefGoogle Scholar
  5. 5.
    Witte I, Foerstermann U, Devarajan A, Reddy ST, Horke S (2012) Protectors or traitors: the roles of PON2 and PON3 in atherosclerosis and cancer. J Lipids 2012:342806. doi:10.1155/2012/342806 PubMedGoogle Scholar
  6. 6.
    Ng CJ, Bourquard N, Grijalva V, Hama S, Shih DM, Navab M, Fogelman AM, Lusis AJ, Young S, Reddy ST (2006) Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2. J Biol Chem 281:29491–29500PubMedCrossRefGoogle Scholar
  7. 7.
    Devarajan A, Bourquard N, Hama S, Navab M, Grijalva VR, Morvardi S, Clarke CF, Vergnes L, Reue K, Teiber JF, Reddy ST (2011) Paraoxonase 2 deficiency alters mitochondrial function and exacerbates the development of atherosclerosis. Antioxid Redox Signal 14:341–351. doi:10.1089=ars.2010.3430 PubMedCrossRefGoogle Scholar
  8. 8.
    Fortunato G, Di Taranto MD, Bracale UM, Del Guercio L, Carbone F, Mazzaccara C, Morgante A, D’ Armiento FP, D’ Armiento M, Porcellini M, Sacchetti L, Bracale G, Salvatore F (2008) Decreased paraoxonase-2 expression in human carotids during the progression of atherosclerosis. Arterioscler Thromb Vasc Biol 28:594–600. doi:10.1161/ATVBAHA.107.154658 PubMedCrossRefGoogle Scholar
  9. 9.
    Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J (2004) Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 28(363):689–695. doi:10.1016/S0140-6736(04)15642-0 CrossRefGoogle Scholar
  10. 10.
    Garin MC, James RW, Dussoix P, Blanché H, Passa P, Froguel P, Ruiz J (1997) Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99:62–66. doi:10.1172/JCI119134 PubMedCrossRefGoogle Scholar
  11. 11.
    Li HL, Liu DP, Liang CC (2003) Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med 81:766–779. doi:10.1007/s00109-003-0481-4 PubMedCrossRefGoogle Scholar
  12. 12.
    Marchegiani F, Spazzafumo L, Provinciali M, Cardelli M, Olivieri F, Franceschi C, Lattanzio F, Antonicelli R (2009) Paraoxonase2 C311S polymorphism and low levels of HDL contribute to a higher mortality risk after acute myocardial infarction in elderly patients. Mol Genet Metab 98:314–318. doi:10.1016/j.ymgme.2009.05.008 PubMedCrossRefGoogle Scholar
  13. 13.
    Gardemann A, Philipp M, Hess K, Katz N, Tillmanns H, Haberbosch W (2000) The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis 152:421–431. doi:10.1016/S0021-9150(99)00489-X PubMedCrossRefGoogle Scholar
  14. 14.
    Welch GN, Loscalzo J (1998) Homocysteine and atherothrombosis. N Engl J Med 338:1042–1050PubMedCrossRefGoogle Scholar
  15. 15.
    Alpert JS, Thygesen K, Antman E, Bassand JP (2000) Myocardial infarction redefined. A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36:959–969. doi:10.1016/S0735-1097(00)00804-4 PubMedCrossRefGoogle Scholar
  16. 16.
    Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF (2007) Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 38:1655–1711. doi:10.1161/STROKEAHA.107.181486 PubMedCrossRefGoogle Scholar
  17. 17.
    Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, Hatsukami TS, Higashida RT, Johnston SC, Kidwell CS, Lutsep HL, Miller E, Sacco RL (2009) AHA/ASA Scientific statement definition and evaluation of Transient Ischemic Attack. Stroke 40:2276–2293. doi:10.1161/STROKEAHA.108.192218 PubMedCrossRefGoogle Scholar
  18. 18.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 289:2560–2572PubMedCrossRefGoogle Scholar
  19. 19.
    Third report of the national cholesterol education program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III), final report. Circulation 106:3143–3421Google Scholar
  20. 20.
    The Expert Committee on the diagnosis and classification of diabetes mellitus (2002) Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 25:S5–S20CrossRefGoogle Scholar
  21. 21.
    Campolo J, De Chiara B, Caruso R, De Maria R, Sedda V, Dellanoce C, Parolini M, Cighetti G, Penco S, Baudo F, Parodi O (2006) Methionine challenge paradoxically induces a greater activation of the antioxidant defence in subjects with hyper- vs normohomocysteinemia. Free Radic Res 40:29–35. doi:10.1080/10715760600801280 CrossRefGoogle Scholar
  22. 22.
    Landmesser U, Harrison DG (2001) Oxidant stress as a marker for cardiovascular events: Ox marks the spot. Circulation 104:2638–2640PubMedGoogle Scholar
  23. 23.
    Heinecke JW, Lusis AJ (1998) Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? Am J Hum Genet 62:20–24PubMedCrossRefGoogle Scholar
  24. 24.
    Précourt LP, Amre D, Denis MC, Lavoie JC, Delvin E, Seidman E, Levy E (2011) The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis 214:20–36. doi:10.1016/j.atherosclerosis.2010.08.076 PubMedCrossRefGoogle Scholar
  25. 25.
    Wang X, Fan Z, Huang J, Su S, Yu Q, Zhao J, Hui R, Yao Z, Shen Y, Qiang B, Gu D (2003) Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in chinese han population. Arterioscler Thromb Vasc Biol 23:328–334. doi:10.1161/01.ATV.0000051702.38086.C1 PubMedCrossRefGoogle Scholar
  26. 26.
    Guxens M, Tomás M, Elosua R, Aldasoro E, Segura A, Fiol M, Sala J, Vila J, Fullana M, Sentí M, Vega G, de la Rica M, Marrugat J (2008) Association between paraoxonase-1 and paraoxonase-2 polymorphisms and the risk of acute myocardial infarction. Rev Esp Cardiol 61:269–275. doi:10.1016/S1885-5857(08)60114-0 PubMedCrossRefGoogle Scholar
  27. 27.
    Pan JP, Lai ST, Chiang SC, Chou SC, An Chiang (2002) The risk of coronary artery disease in population of Taiwan is associated with Cys-Ser 311 polymorphism of human paraoxonase (PON)-2 gene. Zhonghua Yi Xue Za Zh 65:411–412Google Scholar
  28. 28.
    Stoltz DA, Ozer EA, Recker TJ, Estin M, Yang X, Shih DM, Lusis AJ, Zabner J (2009) A common mutation in paraoxonase-2 results in impaired lactonase activity. J Biol Chem 284:35564–35571. doi:10.1074/jbc.M109.051706 PubMedCrossRefGoogle Scholar
  29. 29.
    Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, Cantini R, Campa PP, Ricci G, Arca M (1998) The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol 18:1611–1616. doi:10.1161/01.ATV.18.10.1611 PubMedCrossRefGoogle Scholar
  30. 30.
    Herrmann SM, Blanc H, Poirier O, Arveiler D, Luc G, Evans A, Marques-Vidal P, Bard JM, Cambien F (1996) The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis 126:299–303. doi:10.1016/0021-9150(96)05917-5 PubMedCrossRefGoogle Scholar
  31. 31.
    Chirovsky DR, Fedirko V, Cui Y, Sazonov V, Barter P (2009) Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. Eur J Cardiovasc Prev Rehabil 16:404–442. doi:10.1097/HJR.0b013e32832c8891 PubMedCrossRefGoogle Scholar
  32. 32.
    Ricci C, Battistini S, Cozzi L, Benigni M, Origine P, Verricello L, Lunetta C, Cereda C, Milani P, Greco G, Patrosso MC, Causarano R, Caponnetto C, Giannini F, Corbo M, Penco S (2011) Lack of association of PON polymorphisms with sporadic ALS in an Italian population. Neurobiol Aging 32:552.e7–552.e13. doi:10.1016/j.neurobiolaging.2010.02.010 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • L. Cozzi
    • 1
  • J. Campolo
    • 1
  • M. Parolini
    • 1
  • R. De Maria
    • 1
  • M. C. Patrosso
    • 2
  • A. Marocchi
    • 2
  • O. Parodi
    • 1
  • S. Penco
    • 2
  1. 1.CNR Institute of Clinical Physiology, Cardiothoracic and Vascular DepartmentNiguarda Ca’ Granda HospitalMilanItaly
  2. 2.Laboratory of Medical Genetics, Clinical Chemistry and Clinical Pathology DepartmentNiguarda Ca’ Granda HospitalMilanItaly

Personalised recommendations